Orphan status for cystic fibrosis treatment

The US FDA has granted “orphan” status on BX004 from Israel’s BiomX (see here previously) for the treatment of chronic lung infections suffered by cystic fibrosis patients. Orphan designation is given for rare conditions that have no current treatment.


This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *